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mainly related to the initial response to therapy. Reports ofAcute renal allograft rejection with intimal arteritis: Histologic
biopsies showing type 2A or 2B rejection also should specifypredictors of response to therapy and graft survival.
the degree of tubulitis present, as the latter may significantlyBackground. Acute renal allograft rejection with intimal ar-
influence the initial response to therapy.teritis is designated by the widely used Banff 97 classification
as type 2A or 2B depending on the extent of arteritis, without
regard to interstitial inflammation or tubulitis. We examined
whether the distinction between type 2A and 2B is relevant Acute rejection is manifest on renal transplant biopsyto short- and long-term clinical outcomes, and if outcomes in
as mononuclear inflammatory cell infiltrates in one orthis subset of acute rejection also are affected by tubulitis,
more sites: in the cortical interstitium and tubules (tubul-interstitial inflammation, and several additional histologic and
clinical parameters. itis), beneath the endothelium of arteries (intimal arteri-
Methods. Pathology records were searched to identify cases tis or endothelialitis), and infrequently within both the
of acute renal allograft rejection with intimal arteritis diag- arterial intima and media (transmural arteritis) with ornosed between January 1985 and September 2000. For each
without associated fibrinoid necrosis of the vessel wall.case, the patient’s chart was reviewed to determine the re-
Evidence from a number of studies indicates that thesesponse of the rejection episode to therapy, type(s) of therapy
given, and length of graft survival. All biopsies were reviewed different histologic lesions of acute rejection correlate
and Banff acute and chronic indices recorded by a pathologist with the reversibility of a rejection episode by treatment
blinded to these data. Biopsies not showing type 2A or 2B with corticosteroids and/or other anti-rejection drugs,rejection were excluded, as were repeat biopsies from the same
and with long-term survival of the allograft. Overall,patient and cases with recurrent glomerular disease, viral infec-
lesions characterized by interstitial inflammation and tu-tion, donor-specific antibodies, or more than mild chronic
change. bulitis alone have the greatest likelihood of reversibility
Results. The initial response to anti-rejection therapy was and best prognosis for long-term graft survival, those
significantly worse in patients with type 2B acute rejection with transmural arteritis and/or arterial fibrinoid necrosis
(N  29) than in those with type 2A (N  102) by univariate
the poorest degree of reversibility and graft survival, andand multivariate analyses, despite more aggressive treatment
lesions with intimal arteritis an intermediate prognosisof type 2B rejection. In a Cox proportional hazards model the
with regard to both clinical parameters [1–8].hazard ratio for graft failure for 2B versus 2A was 1.9 (P 
0.05), but this was not significant when adjusted for the initial These clinico-pathologic correlations have led to the
response to therapy. Cases with minimal or mild tubulitis re- development of a number of grading schemata for acute
sponded better to therapy than those with moderate or severe rejection on renal transplant biopsy, the most widelytubulitis, although graft survival was not significantly affected
used of which is the Banff 97 working classification [9].by the tubulitis score.
Banff 97 is a modification of the original (1993) BanffConclusions. The distinction between types 2A and 2B acute
rejection in the Banff 97 classification has significant prognostic schema [10] that also incorporates elements of a second
value with regard to both short- and long-term clinical out- grading system (the NIH/CCTT system [2]), including
comes, although the difference in long-term graft survival is the separation into distinct types (or grades) of acute
rejection of lesions with interstitial inflammation and
tubulitis but without vascular involvement (type 1), withKey words: kidney transplant, Banff 97, tubulitis, acute vascular rejec-
tion, acute cellular rejection. intimal but not transmural arteritis (type 2), and with
transmural arteritis/fibrinoid necrosis (type 3).Received for publication July 2, 2001
In the Banff 97 classification, biopsies showing intimaland in revised form October 30, 2001
Accepted for publication October 31, 2001 (but not transmural) arteritis are designated as showing
type 2B acute rejection if there is severe intimal arteritis 2002 by the International Society of Nephrology
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(Banff index v2) comprising 25% of the luminal area transmural arteritis, and those showing recurrent glo-
merular disease, viral (polyomavirus, cytomegalovirus)of at least one artery, and as type 2A acute rejection if
the degree of intimal arteritis is less than this (Banff infection, or post-transplant lymphoproliferative disease.
Twelve patients (9 with type 2A and 3 with type 2B acuteindex v1). This distinction between type 2A and 2B rejec-
tion is somewhat arbitrary, although in a recent study rejection by the Banff 97 classification) had documented
donor-specific antibodies, and also were eliminated fromof 36 patients with type 2A and 18 patients with type
2B rejection graft loss was significantly greater in the 2B the study. For the remaining 185 biopsies, clinical records
were then reviewed and the following information wasgroup [5]. The designation of a biopsy as showing type
2A or type 2B acute rejection by the Banff 97 schema is recorded: patient age and gender, date of transplant and
post-transplant day on which the biopsy was done, typealso completely independent of the degree of interstitial
inflammation and tubulitis present, although there is of transplant (living-related, living-unrelated, or cadav-
eric), baseline serum creatinine prior to the rejectionsome evidence suggesting that the latter parameters, par-
ticularly tubulitis, may influence the outcome of acute episode prompting the biopsy or if the graft had inade-
quate function between the time of transplantation andrejection episodes with intimal arteritis. In a study in the
pre-cyclosporine era, Matas et al found that seven of the biopsy (delayed graft function; DGF), baseline im-
munosuppressive regimen, type(s) of anti-rejection ther-eighteen grafts with moderate acute vascular rejection
(intimal arteritis) and moderate-to-severe interstitial in- apy given, post-biopsy course including the lowest stable
(for 2 or more daily determinations) serum creatininefiltrate were lost within the first year, although a suffi-
ciently large number of grafts showing intimal arteritis within 20 days of the initiation of therapy and if a subse-
quent biopsy was done, most recent follow-up and serumwith little or no interstitial inflammation were not avail-
able for comparison [4]. Schroeder et al found that creatinine at that time, and date of graft failure (re-
initiation of dialysis) if appropriate.among 29 patients with acute vascular rejection charac-
terized by intimal arteritis treated with OKT3, the poor-
Pathologic review of biopsiesest clinical outcome was in the group of 9 patients with
moderate-to-severe interstitial inflammation and marked Following the review of all clinical records, each biopsy
was assigned a number and all clinical data were recordedtubulitis in addition to the vascular lesion [11]. Further-
more, Nickeleit et al found that in their subset of acute in a table in which only these numbers were present as
identifiers. Microscopic slides from each biopsy were re-rejection episodes with intimal arteritis, increasing tubul-
itis (determined as the number of involved tubules in moved from the files and labeled with these numbers prior
to review.the most affected 10 consecutive high-power microscopic
fields), but not interstitial inflammation, appeared to cor- The slides from each biopsy [routinely stained with
hematoxylin-eosin (H&E), periodic acid-Schiff (PAS),relate with a greater graft failure rate within the first
year post-transplantation [6]. methenamine silver, and Masson’s trichrome] were re-
viewed by a renal pathologist (M.H.) who was blindedThis study retrospectively examined 131 cases of acute
rejection with intimal arteritis in order to specifically from the clinical data. All but two biopsies were needle
biopsies. For each biopsy, the number of tissue coresaddress if the distinction between types 2A and 2B rejec-
tion is relevant to short-term (reversibility of the rejec- (not including any that were all medulla; the two wedge
biopsies were each counted as a single core), the numbertion episode with anti-rejection therapy) and long-term
(graft survival) clinical outcomes. We also examined if of arteries present and the number showing intimal arte-
ritis (v1 or v2), as well as the following parameters werewithin this subset of acute rejection these outcomes are
affected by the degree of interstitial inflammation, tubul- recorded: type of acute rejection by the Banff 97 classifi-
cation, and semiquantitative indices of acute glomerulitisitis, and a number of additional pathologic and clinical
parameters. (g), interstitial inflammation (i), tubulitis (t), arteritis (v),
chronic allograft glomerulopathy (cg), interstitial fibrosis
(ci), tubular atrophy (ct), fibrous intimal thickening of
METHODS
arteries (cv), arteriolar hyaline thickening (ah) and mes-
Patient selection and data collection angial matrix increase (mm). Each index was graded from
0 to 3 (absent or minimal to severe) according to specificComputerized records of the Department of Pathol-
ogy, Johns Hopkins Medical Center were searched to guidelines established in the Banff 97 schema [9]. As some
biopsies with minimal or mild interstitial inflammationidentify all renal transplant biopsies potentially showing
intimal arteritis that were interpreted from January 1985 did show more extensive interstitial edema, an “edema
score” also was determined for each biopsy, based on anthrough September 2000. The individual biopsy reports
were then reviewed to eliminate all repeat biopsies (of estimate of the fraction of cortical tissue with edema: 0,
10%; 1, 10–25%; 2, 26–50%; 3,50%. Findings of acutethe same allograft or of a subsequent graft in the same
patient), as well as cases without intimal arteritis or with tubular injury not associated with apparent foci of acute
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rejection and histologic evidence of cyclosporine/tacroli- within 20 days of initiation of therapy showed no acute
mus nephrotoxicity [12, 13] were recorded when present. rejection (the latter defined as Banff 97 type 1A or
On the basis of this review 19 biopsies were excluded greater) on an adequate sample with 10 glomeruli and
from the study: 10 did not show lesions believed to be 2 arteries [9]. A partial response occurred if there was
diagnostic of intimal arteritis, 2 showed transmural arte- a reduction in serum creatinine with therapy, but only
ritis, and 7 did not have adequate tissue for evaluation to within 126 to 175% of the pre-rejection baseline value;
of the above indices. As this study was designed to con- for DGF cases recovery of serum creatinine to within
sider only the outcome of acute rejection episodes, we the range of 1.5 to 2.9 mg/dL was considered a partial
also eliminated from the study an additional 26 biopsies response. A partial response was also considered to have
showing more than mild chronic change, as defined by occurred if a repeat biopsy within 20 days of initiation
a chronic allograft nephropathy (CAN) score (cg  ci  of therapy showed a lower grade of acute rejection
ct  cv  ah  mm) 6, or (ci  ct) 3. (Banff 97 type 1A or greater) than was present on the
Following complete clinical and pathologic reviews, original biopsy, on an adequate sample as defined above.
140 biopsies (from 140 different patients) remained that
met all study criteria. We were able to obtain complete Statistical analysis
follow-up information (initial response to anti-rejection
Clinical and pathologic data, devoid of personal identi-therapy and subsequent graft survival for a minimum of
fiers, were entered into an electronic database and the3 months post-biopsy or until graft failure) for 131 of
accuracy of data transcription was independently con-these patients; the latter then comprised the study popu-
firmed. The distribution of variables was examined usinglation used for analysis of treatment response and graft
the Shapiro-Wilks test and q-q plots. Outlying values weresurvival. One hundred two biopsies showed type 2A
identified using box plots and their accuracy checkedacute rejection and 29 type 2B acute rejection. All study
against the original source data. Normally distributedprocedures were approved by the Joint Committee on
continuous data were summarized using means and stan-Clinical Investigation of the Johns Hopkins Hospital.
dard deviations (SD) and were compared across groups
Data analysis using independent sample t tests. Markedly skewed data
were summarized as medians and intra-quartile rangesFor descriptive analyses categorical variables were di-
(IQR) and were compared across groups using the Mann-vided into two or three groups of similar size, in as much
Whitney test. Categorical data were expressed as percent-as the data allowed. For multivariate analysis variables
were dichotomized in order to help avoid over-parame- ages and compared using Fisher’s exact test for dichoto-
terizing the statistical models. mous variables or otherwise by the chi square test.
To facilitate analysis of short-term responses of acute The association of the Banff v score (v1 versus v2)
rejection episodes to therapy, treatments given were di- with short-term response to therapy was examined using
vided into three broad categories: (1) steroids only con- unconditional logistic regression. To examine the inde-
sisted of pulse intravenous methylprednisolone, with or pendence of this association from the other Banff acute
without additional oral prednisone; (2) steroids plus con- indices the v score was simultaneously adjusted for g, i
sisted of the above plus an increase in the dose of tacroli- and t scores using multivariate regression. To examine
mus or cyclosporine and/or addition of mycophenolate the potential influence of other variables the v score was
mofetil; and (3) antibody therapy consisted of OKT3, adjusted for each variable for which data were available
thymoglobulin, or Atgam, with or without additional in separate analyses.
change(s) in immunosuppressive therapy. All but four Long-term graft outcome was measured from the time
patients receiving antibody (3 with type 2A acute rejec-
of transplantation and was examined by time to event
tion, 1 with type 2B) also received steroids, and in most
analysis using the Kaplan-Meier method and log rankinstances steroids and antibody were administered con-
testing. Patients who died with functioning grafts werecurrently. Five patients (3 with type 2A rejection, 2 with
censored at that time. The independence of v score (thattype 2B) received antibody after failing to respond to a
is, type 2A vs. type 2B acute rejection) regarding graftcourse of steroids; in these cases the response to therapy
survival was examined using Cox proportional hazardsanalyzed (see below) was that to the antibody.
modeling. More extensive modeling was not attemptedThe response of each rejection episode to anti-rejec-
due to the limited available sample size. Routine modeltion therapy was graded according to criteria previously
checking was performed using analysis of residuals fordefined by Gaber et al [1]. A complete response to ther-
the logistic regression and visual inspection of log-logapy occurred if the post-treatment serum creatinine re-
plots for the Cox model. All analyses were two-tailed andturned to 125% of the pre-rejection baseline value or
used a type I error rate of 0.05. Analyses were performedfor cases of DGF, to 1.4 mg/dL. A complete response
also was considered to have occurred if a repeat biopsy using SPSS Base 7.5 (SPSS Inc., Chicago, IL, USA).
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Table 1. Baseline clinical characteristics and histological findings of 131 renal allograft recipients
at first biopsy proven episode of Banff 97 type 2 rejection
Banff type
All subjects
Parameter (N131) 2A (N102) 2B (N29) P
Baseline clinical data
Age years, mean (SD)a 43.3 (15.9) 43.0 (15.6) 44.5 (17.0) 0.66
Gender
Male 72 (55%) 53 (52%) 19 (65.5%)
Female 59 (45%) 49 (48%) 10 (34.5%) 0.21
Transplant type
Cadaveric 82 (62.6%) 60 (58.8%) 22 (75.9%)
Living 49 (37.4%) 42 (41.2%) 7 (24.1%) 0.09
Time to biopsy days
Median (IQR) 12 (28) 11 (24.5) 16 (38.5) 0.52
Biopsy indication
Delayed graft function 58 (44.3%) 46 (45.1%) 12 (41.4%)
Rise in serum creatinine 73 (55.7%) 56 (54.9%) 17 (58.6%) 0.72
Baseline immunosuppression
with mycophenolate/rapamycin 81 (61.8%) 66 (64.7%) 15 (51.7%)
without mycophenolate/rapamycin 50 (38.2%) 36 (35.3%) 14 (48.3%) 0.30
Treatmentb
Steroids only 41 (31.3%) 38 (37.3%) 3 (10.3%)
Steroids plus 30 (22.9%) 23 (22.5%) 7 (24.1%)
Antibody therapy 60 (45.8%) 41 (40.2%) 19 (65.5%) 0.02
Pathology data
g score
0 53 (40.5%) 42 (41.2%) 11 (37.9%)
1 59 (45.0%) 49 (48.0%) 10 (34.5%)
2–3 19 (14.5%) 11 (10.8%) 8 (27.6%) 0.07
i score
0–1 23 (17.6%) 19 (18.6%) 4 (13.8%)
2 35 (26.7%) 31 (30.4%) 4 (13.8%)
3 73 (55.7%) 52 (51.0%) 21 (72.4%) 0.11
t score
0–1 57 (43.5%) 45 (44.1%) 12 (41.4%)
2 39 (29.8%) 27 (26.5%) 12 (41.4%)
3 35 (26.7%) 30 (29.4%) 5 (17.2%) 0.23
Unmodified acute SUM scorec
1–5 47 (35.9%) 43 (42.2%) 4 (13.8%)
6–7 50 (38.2%) 38 (37.3%) 12 (41.4%)
8–10 34 (26.0%) 21 (20.6%) 13 (44.8%) 0.006
Chronic allograft nephropathy score
0–1 60 (45.8%) 45 (44.1%) 15 (51.7%)
2–4 43 (32.8%) 35 (34.3%) 8 (27.6%)
5–6 28 (21.4%) 22 (21.6%) 6 (20.7%) 0.74
Edema scored
0–1 27 (20.6%) 22 (21.6%) 5 (17.2%)
2 43 (32.8%) 36 (35.3%) 7 (24.1%)
3 61 (46.6%) 44 (43.1%) 17 (58.7%) 0.33
Acute tubular necrosis
No 121 (92.4%) 94 (92.2%) 27 (93.1%)
Yes 10 (7.6%) 8 (7.8%) 2 (6.9%) 0.87
Tacrolimus/cyclosporine toxicity
No 98 (74.8%) 77 (75.5%) 21 (72.4%)
Yes 33 (25.2%) 25 (24.5%) 8 (27.6%) 0.75
a Abbreviations are: SD, standard deviation; IQR, intraquartile range
b Definitions are: steroids only, pulse intravenous corticosteroid; steroid plus, pulse intravenous corticosteroid with increased tacrolimus/cyclosporine dose and/or
the addition of mycophenolate; antibody therapy, antibody therapy with or without other interventions. (Details of therapy are in Fig. 2)
c Sum of individual Banff indices, (g  i  t  v)
d Estimated fraction of cortical tissue present with edema: 0, 10%; 1, 10–25%; 2, 26–50%; 3, 50%
RESULTS ous kidney-pancreas grafts), 31.3% a living-related graft
and 6.1% a living-unrelated graft. The median time fromDemographic data for the 131 patients with biopsies
transplantation to biopsy was 12 days (range 3 to 2484meeting study entry criteria and having complete data
days). The indication for biopsy was DGF in 58 casesavailable for analysis are listed in the upper portion of
and a rise in serum creatinine in 73. The biopsy indicationTable 1. Fifty-five percent of the patients were male,
62.6% received a cadaveric graft (including 3 simultane- was strongly correlated with time post-transplantation,
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Fig. 1. Histopathologic lesions of acute rejec-
tion as defined by Banff 97 classification. (A)
Mild to moderate intimal arteritis (Banff in-
dex v1); there are multiple mononuclear in-
flammatory cells directly beneath the endo-
thelium but with 25% reduction in luminal
area (H&E, 400). (B) Severe intimal arteri-
tis (v2), with subendothelial mononuclear
cells, edema, and fibrin resulting in 25% re-
duction in luminal area (H&E, 400). (C )
Moderate tubulitis (t2); two tubular cross-sec-
tions (arrows) contain between 5 and 10 infil-
trating mononuclear inflammatory cells. Note
the accompanying interstitial inflammation
(PAS, 400). (D) Severe tubulitis (t3), with
10 infiltrating mononuclear inflammatory
cells in multiple tubular cross sections (arrows).
The surrounding interstitium is edematous with
mononuclear cell infiltrate (PAS, 400).
with DGF being the indication for 71% (27 of 38) of (Banff index t2) and severe (t3) tubulitis, with 5 to 10
and 10 mononuclear cells, respectively, in the mostbiopsies done during the first 7 days after the transplant,
51% (30 of 59) of biopsies done between days 8 and 30, involved tubular cross-sections.
Of the 131 biopsies included in this study, 101 hadand only 3% (1 of 34) of biopsies performed after day
30 (P  0.001). Cases of type 2A versus 2B rejection been assigned a Banff acute rejection type (grade) at
the time of original diagnosis, 25 by the pathologist whodid not differ significantly with respect to patient age,
transplant type, mean time from transplant to biopsy, performed slide reviews for this study and 76 by another
renal pathologist. In all 25 of the former cases and in 73biopsy indication, or baseline immunosuppression (use
of mycophenolate mofetil or rapamycin versus azathio- of the latter 76, the original and review diagnoses were
in agreement, taking into account differences betweenprine or none of these three agents). However, cases of
type 2B rejection were treated more aggressively: 19 the original (1993) Banff and Banff 97 schemata regard-
ing typing of specific histologic lesions of acute rejection(66%) of these 29 patients received antibody therapy
(15 OKT3, 4 thymoglobulin) and only 3 (10%) cortico- [9, 10]. Two biopsies originally diagnosed as showing
type 2A acute rejection were believed to have type 2Bsteroids alone. By contrast, 41 (40%) of the 102 patients
with type 2A rejection received antibody therapy (32 rejection on review, and one case originally diagnosed as
type 2B rejection was thought to show type 2A. BiopsiesOKT3, 6 thymoglobulin, 3 Atgam) and 38 (37%) re-
ceived corticosteroids alone (Table 1). showing type 2A versus type 2B acute rejection did not
differ significantly with respect to the mean number ofThe histopathologic lesions of acute rejection as de-
fined by the Banff 97 classification [9] are illustrated in tissue cores (2.0  0.8 vs 1.9  0.6, mean  SD), or the
mean (6.2  3.2 vs. 6.4  3.3) or median number ofFigure 1. Figure 1 A and B show lesions of intimal arteri-
tis, with mononuclear inflammatory cells beneath the arteries (6, range 2 to 15 vs. 5, range 2 to 16) present per
biopsy. However, the percentage of visualized arteriesendothelium, accompanied by edema fluid and fibrin in
the artery shown in Figure 1B. In the latter artery this showing intimal arteritis (v1 or v2) was significantly
higher in biopsies with type 2B rejection (median 36%,inflammatory process results in loss of 25% of the
luminal area, which defines a lesion of severe intimal range 17 to 100%) than in those with type 2A (median
25%, range 7 to 67%; P  0.001).arteritis (Banff index v2) and is required for diagnosis
of Banff 97 type 2B acute rejection. In the artery shown Histopathologic features of the 131 biopsies are sum-
marized in the lower portion of Table 1. As noted above,in Figure 1A, the degree of luminal obstruction is less
than 25%, defining a lesion of mild to moderate intimal 102 of the biopsies showed mild-to-moderate intimal ar-
teritis (Banff 97 index v1, type 2A acute rejection) whilearteritis (Banff index v1) and a diagnosis of type 2A
acute rejection. Figure 1 C and D illustrate moderate 29 showed severe intimal arteritis (index v2, type 2B
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Fig. 2. Comparison of responses of types 2A
and 2B acute rejection episodes to anti-rejec-
tion therapy. Criteria for complete and partial
responses as well as therapeutic categories are
defined in the Methods section; cases showing
neither a complete or partial response are cat-
egorized as showing no response. Within each
therapeutic category, the percent of cases with
complete, partial, and no response to therapy
are shown. Of the 60 patients receiving anti-
body, 47 received OKT3, 10 thymoglobulin,
and 3 Atgam; all but 4 of the patients receiving
antibody also received steroids. Additional
therapies in the Steroids Plus patients in-
cluded increased tacrolimus dosage (25 cases),
increased tacrolimus plus mycophenolate mo-
fetil (2), increased cyclosporine (1), increased
cyclosporine plus mycophenolate mofetil (1)
and mycophenolate mofetil (1). Symbols are:
( ) complete response; ( ) partial response;
() no response.
acute rejection). Banff acute SUM scores (g i t v) and the modified acute SUM score (g i t). Interstitial
inflammation, glomerulitis, edema score, CAN score,were significantly higher in biopsies showing 2B lesions,
in part because the v score is included within this SUM, presence or absence of ATN or calcineurin inhibitor
toxicity, baseline immunosuppression and type of anti-although a modified acute SUM (g  i  t) without the
v component was 5 in 86% of 2B lesions versus 58% rejection therapy given were not significantly associated
with treatment response, although the response was sig-of 2A (P  0.005). There was also a trend toward more
glomerulitis (g) and interstitial inflammation (i) in the nificantly worse (that is, higher odds of partial/no re-
sponse) in patients with DGF than in those biopsied for2B biopsies, although this was not statistically significant.
There were no significant differences between biopsies a rise in serum creatinine. As noted in Table 3, the v
and t indices as well as indication for biopsy remainedwith type 2A versus 2B acute rejection with respect to
tubulitis (t), CAN score, edema score, the presence or significant predictors of initial response to therapy in
a multivariate analysis adjusting for each of the listedabsence of acute tubular injury (ATN, in areas of the
biopsy not appearing to be directly involved by acute parameters. In addition, the v score remained significant
when adjusted in separate analyses for the modifiedrejection) and histologic evidence of cyclosporine/tacrol-
imus nephrotoxicity. acute SUM score, CAN score, and other parameters
listed in Table 2 (data not shown).
Short-term outcome
Long-term follow-upBy univariate analysis, there was a significant differ-
ence between type 2A (v1) and type 2B (v2) acute rejec- The cohort provided a total of 290 patient-years of
follow-up, 81% of which was provided by patients withtion episodes with regard to initial response to anti-rejec-
tion therapy: 52.0% versus 10.3% showed a complete type 2A acute rejection. The median follow-up interval
post-biopsy for patients whose grafts continued to func-response, 37.3% versus 51.7% a partial response, and
10.8% versus 37.9% no response, respectively (Fig. 2). tion at the end of the observation period was 20 months
(range 3 to 157). As shown in Table 4, the incidence ofThis difference occurred despite the more aggressive
treatment of type 2B rejection (Fig. 2; also see in prior graft failure was significantly higher with type 2B as
compared with type 2A acute rejection. The mean dura-section). As shown in Table 2, the odds ratio for failing to
obtain a complete response to therapy was significantly tion of follow-up and median serum creatinine levels in
surviving grafts were not significantly different betweenassociated not only with the v score, but also with the
extent of tubulitis (absent or mild vs. moderate to severe) these two groups.
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Table 2. Univariate associations of arteritis score, baseline clinical characteristics and other histological findings with partial/no response
as compared with complete short-term response to therapy
Odds ratio 95% CIa P
Arteritis score
v score
v1 Ref
v2 9.4 2.7, 32.9 0.001
Baseline clinical characteristics
Age years 1.01 0.99, 1.04 0.27
Gender
Female Ref
Male 1.42 0.71, 2.85 0.33
Transplant type
Living Ref
Cadaveric 2.0 0.96, 4.02 0.07
Duration transplantation-biopsy
7 days 0.90 0.39, 2.05 0.79
8–30 days Ref
30 days 1.49 0.63, 3.50 0.36
Biopsy indication
Rise in serum creatinine Ref
Delayed graft function 2.77 1.33, 5.73 0.006
Baseline immunosuppression
without mycophenylate/rapamycin Ref
with mycophenylate/rapamycin 0.95 0.47, 1.94 0.89
Treatment
Steroids only Ref
Steroids plus 0.50 0.19, 1.31 0.16
Antibody 2.02 0.88, 4.60 0.10
Other histological findings
g score
0 Ref
1–3 0.81 0.40, 1.64 0.55
i score
0–2 Ref
3 1.70 0.85, 3.42 0.14
t score
0–1 Ref
2–3 3.05 1.48, 6.27 0.002
Modified acute SUM scoreb
1–5 Ref
6–9 2.23 1.08, 4.61 0.03
Edema scorec
0–1 Ref
2 1.34 0.54, 3.33 0.53
3 1.04 0.47, 2.29 0.93
Chronic allograft nephropathy score
0–1 Ref
2–6 1.19 0.59, 2.37 0.63
Acute tubular necrosis
Yes Ref
No 2.13 0.57, 7.94 0.26
Tacrolimus/cyclosporine toxicity
Yes Ref
No 0.98 0.44, 2.18 0.96
a Abbreviations: CI, confidence interval; Ref, reference category
b Sum of individual Banff indices, excluding v, (g  i  t)
c Estimated fraction of cortical tissue present with edema: 0, 10%; 1, 10–25%; 2, 26–50%; 3, 50%
Figure 3 shows unadjusted Kaplan-Meier graft sur- only other variables significantly associated with graft
survival were response to therapy with a partial responsevival curves for types 2A and 2B acute rejection. Median
graft survival from the time of transplantation was 7.5 and no response being associated with relative hazards
of 3.3 and 22.8, respectively, compared with a completeyears (95% CI, 3.0 to 12.0) for type 2A versus 4.6 years
(95% CI, 0.4 to 8.8) for type 2B (P  0.05). Using the response, the interval between transplantation and biopsy,
and interstitial inflammation. In the latter instances, re-Cox proportional hazards model (Table 5), the relative
hazard of graft failure with type 2B rejection (v2 lesion) jection episodes diagnosed more than 30 days post-trans-
plantation were associated with a poorer graft survivalas compared with type 2A (v1) was 1.9 (P  0.05). The
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Table 3. Multivariate logistic regression of partial/no response as of type 2B acute rejection than in those of type 2A,
compared to complete response to treatment
although most or all of this difference in long-term prog-
Adjusted nosis is related to the initial response to therapy. Our
odds ratio 95% CIa P findings are in agreement with those of Minervini et al,
v score who found a greater incidence of graft loss among 18
v1 Ref
patients with v2 intimal arteritis (type 2B acute rejection)v2 13.2 3.3, 52.7 0.001
Biopsy indication than among 36 patients with v1 intimal arteritis (type
Rise in serum creatinine Ref 2A) [5]. Together, these studies appear to validate the
Delayed graft function 6.34 2.34, 17.17 0.001
distinction between types 2A and 2B acute rejection int score
0–1 Ref the Banff 97 schema.
2–3 5.0 1.90, 13.20 0.001 Another aim of this study was to determine if the
i score
short- and long-term outcomes of acute rejection with0–2 Ref
3 1.56 0.58, 4.18 0.38 intimal arteritis are affected by the extent of interstitial
g score inflammation and/or tubulitis present. In biopsies with-
0 Ref
out arteritis these parameters, and especially tubulitis,1–3 0.88 0.36, 2.12 0.77
define whether a biopsy shows acute rejection, and thea Abbreviations: CI, confidence interval; Ref, reference category
type of rejection present (borderline, types 1A and 1B)
according to the Banff 97 classification. In at least some
studies, the type of acute rejection in these latter biopsies
is a significant prognostic indicator of both response to
than earlier rejection episodes, and moderate interstitial anti-rejection therapy (particularly corticosteroids) and
inflammation (Banff 97 index i2) was associated with long-term graft function [3, 5, 14], and there is also some
better graft survival than minimal or mild inflammation evidence suggesting that more extensive tubulointersti-
(i0 to i1). Notably, the extent of tubulitis was not signifi- tial inflammation may adversely affect outcomes in acute
cantly associated with graft survival. As shown in the rejection with intimal arteritis [6, 11]. In our 131 cases
right side of Table 5, the deleterious effect of v2 versus of types 2A and 2B acute rejection, the initial response to
v1 lesions with regard to graft survival was modestly therapy was significantly better when the biopsy showed
attenuated by adjusting for transplant type, acute glo- absent or mild tubulitis (fewer than 5 lymphocytes in
merulitis (g) score and modified acute SUM score, but the most involved tubular cross-section) than when mod-
only marginally influenced by adjustment for the other erate or severe tubulitis was present. However, long-
various histologic and baseline clinical parameters exam- term graft survival was not significantly associated with
ined. However, when adjusted for the short-term re- the degree of tubulitis present. Nickeleit et al found in
sponse to treatment the prognostic effect of the v score 57 cases of acute rejection with intimal arteritis a trend
on graft survival was abolished. toward increasing graft failure at one year post-biopsy
when there was also a prominent degree of tubulitis
(7 non-atrophic tubular cross-sections with at least oneDISCUSSION
invading mononuclear cell in 10 consecutive high power
The primary objective of this study was to determine microscopic fields), although as in our study this did not
if the distinction between types 2A and 2B acute rejec- reach statistical significance [6].
tion, as defined in the Banff 97 working classification of Consistent with findings of others [6, 15], we found
renal allograft pathology [9], is justified based on short- no evidence that increasing interstitial inflammation
and long-term clinical outcomes. Although the clinical worsened the short- or long-term prognosis in cases of
relevance of most aspects of the Banff schema has been acute rejection with intimal arteritis. Somewhat surpris-
tested in multiple studies and shown to have prognostic ingly, such rejection episodes with moderate interstitial
significance with regard to both reversibility of acute inflammation (Banff index i2) had a better outcome than
rejection episodes and long-term graft survival [1, 3, 5, those with minimal or mild (i0 or i1) inflammation. Nick-
14], only very limited examination of the validity of sub- eleit et al also found a similar trend in their cases of type
classifying type 2 rejection on the basis on the degree of 2 acute rejection, with lesions having 11 to 25% cortical
intimal arteritis present has been done. Our data show infiltrate (an amount corresponding to Banff index i1)
that patients with type 2B acute rejection have a much being associated with a worse 1-year graft survival than
lower likelihood of showing a complete response to anti- those with more widespread interstitial infiltrate, al-
rejection therapy than patients with type 2A acute rejec- though the number of cases in the former group was
tion (10 vs. 52%), and a greater likelihood of having small and the difference was not statistically significant
neither a complete or partial response to therapy (38 vs. [6]. The reason(s) for this apparent “protective” effect
of moderate interstitial inflammation are not clear, al-11%). The odds of graft failure are also higher in cases
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Table 4. Renal allograft outcome among 131 recipients with biopsy proven Banff 97 type 2 acute rejection
Banff 97 Type
All subjects
(N131) 2A (N102) 2B (N29) P
Short-term response to treatment
No response, N (%) 22 (16.8%) 11 (10.8%) 11 (37.9%)
Partial response, N (%) 53 (40.5%) 38 (37.3%) 15 (51.7%)
Complete response, N (%) 56 (42.7%) 53 (52.0%) 3 (10.3%) 0.001
Long-term graft survival
Follow-up status, N (%)
Functional 91 (69.5%) 75 (73.5%) 16 (55.2%) 0.07
Failed 40 (30.5%) 27 (26.5%) 13 (44.8%)
Survival years, median (SE) 4.7 (1.2) 7.5 (2.3) 4.6 (2.2) 0.05
Incidence rate of graft failure, (failures per graft-year) 1 per 7.25 1 per 8.7 1 per 4.2 0.04
Serum creatinine at last follow-up, mg/dL, median (IQR) 1.65 (0.93) 1.60 (0.95) 1.80 (1.23) 0.36
Abbreviations are: SE, standard error; IQR, intraquartile range.
though it would appear unlikely to be related to the
inclusion of significant numbers of cases with a compo-
nent of antibody-mediated acute rejection in our study
population. We specifically excluded patients with docu-
mented anti-donor antibodies; however, it is certainly
possible that some cases of acute rejection with an undoc-
umented humoral component were included, particu-
larly from early in the study interval before histologic
[16] and more recently immunohistologic [17] findings
correlating with the presence of donor-specific antibod-
ies (and thus prompting testing for such antibodies) were
described. While biopsies of acute rejection with a hu-
moral component (“accelerated” acute rejection) not in-
frequently show scant interstitial inflammation [18],
Trpkov et al found that minimal to mild tubulitis (Banff
indices t0 and t1), but not a specific degree of interstitial
inflammation, correlated strongly with the presence of Fig. 3. Kaplan-Meier plots of unadjusted renal allograft survival from
the time of transplantation among patients with Banff 97 type 2A (N donor-specific antibodies in acute renal allograft rejec-
102) and type 2B (N  29) acute rejection. P  0.05.tion [16]. The finding that minimal-to-mild tubulitis also
correlated with a good outcome (particularly short-term)
in the present study argues against cases with antibody-
mediated rejection explaining our findings regarding in- Biopsies with a chronic allograft nephropathy (CAN)
terstitial inflammation. score (Banff 97 indices cg  ci  ct  cv  ah  mm)
Gaber and coworkers [1] and others [19, 20] have 6, or with chronic indices (ci  ct) 3 were excluded
advocated the use of the acute SUM score, comprised from this study. These thresholds are somewhat arbi-
of Banff indices (g  i  t  v), in the evaluation of trary, but were chosen to exclude cases with more than
acute renal allograft rejection. In the series of Gaber et mild CAN as it was the aim of this study to focus specifi-
al the reversal of acute rejection with corticosteroids cally on outcomes in acute rejection. It is well docu-
correlated with the acute SUM score and the vascular mented that CAN is an independent risk factor for the
(v) score [1]. There was no significant correlation with development of graft dysfunction [21–23]. In a study
individual g, i, or t scores. In cases of acute rejection of patients who underwent protocol biopsies of renal
with intimal arteritis, the present study similarly showed allografts, the CAN score and (ci  ct) 6 months post-
the v score to be an independent prognostic indicator of transplantation both correlated significantly with the rate
clinical outcomes, and a higher modified acute SUM of decline in serum creatinine over the ensuing 18 months
score (without the v component; g i t) also correlated [21]. In a similar study of protocol biopsies taken 6
significantly with a poorer initial response to therapy. months post-transplantation, grafts with 25% intersti-
However, the modified acute SUM score did not have tial fibrosis (roughly equivalent to Banff ci index 2)
a statistically significant correlation with long-term graft had a significantly lower survival rate than those with
25% interstitial fibrosis (ci 1) [22]. In protocol biop-survival.
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Table 5. Association of crude and adjusted arteritis score and other unadjusted potential predictors on time to graft failure
Arteritis score (v2 vs. v1)
Crude HR 95% CI P c
1.9 0.99, 3.77 0.05
Potential explanatory variables Crude HRa 95% CI P Adjusted HRb 95% CI P c
Age years 1.00 0.98, 1.03 0.68 1.93 0.99, 3.76 0.05
Gender
Male Ref
Female 0.79 0.41, 1.49 0.46 1.89 0.97, 3.70 0.06
Transplant type
Cadaveric Ref
Living 0.59 0.29, 1.18 0.13 1.76 0.89, 3.48 0.11
Duration transplant-biopsy
7 days 1.63 0.66, 4.07 0.29
8–30 days Ref
30 days 2.61 1.27, 5.35 0.009 2.34 1.18, 4.65 0.02
Biopsy indication
Delayed graft function Ref
Rise in serum creatinine 0.76 0.39, 1.47 0.41 1.89 0.96, 3.70 0.06
g score
0 Ref
1 0.81 0.40, 1.65 0.57
2–3 1.58 0.67, 3.75 0.30 1.76 0.87, 3.56 0.12
i score
0–1 Ref
2 0.34 0.12, 0.94 0.04
3 0.55 0.26, 1.17 0.12 2.04 1.00, 4.12 0.05
t score
0–1 Ref
2 1.28 0.62, 2.62 0.50
3 1.39 0.62, 3.12 0.42 1.98 1.00, 3.89 0.05
Modified acute SUM score
1–5 Ref
6–9 1.17 0.60, 2.28 0.64 1.71 0.82, 3.59 0.16
CAN score
0–1 Ref
2–4 0.95 0.43, 2.1 0.91
5–6 1.83 0.87, 3.87 0.11 1.97 1.00, 3.86 0.05
Acute tubular necrosis
No Ref
Yes 0.65 0.16, 2.71 0.56 1.92 0.98, 3.74 0.06
Tacrolimus/CsA toxicity
No Ref
Yes 0.65 0.29, 1.49 0.31 1.93 0.99, 3.77 0.05
Initial response to treatment
Complete Ref
Partial 3.3 1.3, 8.70 0.01
None 22.83 8.85, 58.91 0.001 0.58 0.27, 1.25 0.17
Treatment
Steroids only Ref 1.87 0.94, 3.69 0.07Steroids plus 0.76 0.29, 2.02 0.58
Antibody 1.16 0.58, 2.33 0.67
a Abbreviations: HR, hazard ratio; CI, confidence interval; Ref, reference category; CsA, cyclosporine
b Adjusted hazard ratio for arteritis score adjusted individually in separate analyses for the adjacent potential explanatory variable
c P value for comparison of time to graft failure for v2 vs. v1, either unadjusted (first row) or adjusted separately for each listed variable
sies taken two years post-transplantation, it was found short-term clinical outcome compared with those of an
initially functioning graft presenting with a rise in serumthat a six-component “chronic allograft damage index,”
in which five of the components are identical to those creatinine. It remains debated whether DGF correlates
with reduced graft survival independent of acute rejec-in the CAN score, was a significant and independent
predictor of deterioration in graft function over the ensu- tion [24]. Still, in the context of our findings it is of
interest that Marce´n et al reported that the negativeing two years [23].
Among clinical parameters, we found that cases of impact of acute rejection in the first month post-trans-
plantation on one- and six-year graft survival rates wastype 2 acute rejection associated with DGF had a worse
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5. Minervini MI, Torbenson M, Scantlebury V, et al: Acute renalsignificantly greater in patients with DGF than in those
allograft rejection with severe tubulitis (Banff 1997 grade 1B). Amwithout DGF [24]. We also found that rejection episodes J Surg Pathol 24:553–558, 2000
diagnosed more than 30 days post-transplantation were 6. Nickeleit V, Vamvakas EC, Pascual M, et al: The prognostic
significance of specific arterial lesions in acute renal allograft rejec-associated with a poorer graft survival than those diag-
tion. J Am Soc Nephrol 9:1301–1308, 1998nosed earlier in the post-transplant course. This is consis-
7. Magil A, Rubin J, Ladewig L, et al: Renal biopsy in acute allograft
tent with several previous studies that found that late rejection. Significance of moderate vascular lesions in long-term
acute rejection episodes (defined in these studies as 60 graft survival. Nephron 26:180–183, 1980
8. Kooijmans-Coutinho MF, Hermans J, Schrama E, et al: Intersti-days post-transplantation) were associated with more
tial rejection, vascular rejection, and diffuse thrombosis of renalfrequent development of chronic rejection/CAN and allografts. Transplantation 61:1338–1344, 1996
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